Loss-of-function variants reduce P/Q-type calcium channel function leading to synaptic deficits and increased intrinsic neuronal excitability via diminished potassium channel function
Target Population
Patients with heterozygous loss-of-function CACNA1A variants exhibiting variable neurological phenotypes
Care Setting
Neurology and neurodevelopmental disorder clinical settings with potential for therapeutic intervention
Key Highlights
CACNA1A haploinsufficiency leads to reduced synaptic number and strength with altered network synchronization in human iPSC-derived glutamatergic neurons.
Increased intrinsic neuronal excitability is mediated by reduced potassium channel function and expression, despite synaptic deficits.
Pharmacological modulation with 4-aminopyridine and small conductance calcium-activated potassium channel activators partially reverses network dysfunction.
Guideline-Based Recommendations
Diagnosis
Consider genetic testing for CACNA1A variants in patients with cerebellar ataxia, epilepsy, intellectual disability, or neurodevelopmental disorders.
Use electrophysiological and gene expression analyses to characterize neuronal network dysfunction in suspected CACNA1A haploinsufficiency.
Management
Therapeutic use of 4-aminopyridine may mitigate network excitability abnormalities in episodic ataxia type 2 related to CACNA1A loss-of-function.
Positive modulation of small conductance calcium-activated potassium channels represents a potential therapeutic strategy.
Monitoring & Follow-up
Monitor neurological symptoms including ataxia, seizure activity, and cognitive function longitudinally in patients with CACNA1A haploinsufficiency.
Risks
Variable clinical phenotypes ranging from ataxia to epilepsy and intellectual disability require individualized risk assessment.
Patient & Prescribing Data
Individuals with heterozygous loss-of-function CACNA1A variants presenting with neurological symptoms
4-aminopyridine shows partial efficacy in restoring network function; potassium channel modulators may offer additional benefit
Clinical Best Practices
Utilize human iPSC-derived neuronal models to study CACNA1A haploinsufficiency mechanisms and test therapeutic agents.
Incorporate electrophysiological assessments to detect synaptic and intrinsic excitability changes in patient-derived neurons.
Apply precision medicine approaches targeting potassium channel function to address increased neuronal excitability.
by Marina P Hommersom, Nina Doorn, Sofía Puvogel, Elly I Lewerissa, Annika Mordelt, Ummi Ciptasari, Franziska Kampshoff, Lieke Dillen, Ellen van Beusekom, Astrid Oudakker, Naoki Kogo, Amalia M Dolga, Monica Frega, Dirk Schubert, Bart P C van de Warrenburg, Nael Nadif Kasri, Hans van Bokhoven
This Neuroscience Grand Rounds session, led by Muhammad Osama, MD, provides a pediatric neurosurgeon’s perspective on arteriovenous malformations (AVMs) in children, rare but high-risk vascular lesions that can lead to seizures, neurological deficits, or life-threatening hemorrhage.
